Prolyl-Hydroxylase Inhibitors

Compounds that inhibit the action of HYDROXYLASES that act on PROLINE to form HYDROXYPROLINE.

Also Known As:

Proline Dioxygenase Inhibitors; Proline Hydroxylase Inhibitors; Dioxygenase Inhibitor, Proline; Dioxygenase Inhibitors, Proline; Hydroxylase Inhibitor, Proline; Hydroxylase Inhibitor, Prolyl; Hydroxylase Inhibitors, Proline; Inhibitor, Proline Dioxygenase; Inhibitor, Proline Hydroxylase; Inhibitor, Prolyl Hydroxylase; Inhibitor, Prolyl-Hydroxylase; Inhibitors, Proline Dioxygenase; Inhibitors, Proline Hydroxylase; Inhibitors, Prolyl-Hydroxylase; Prolyl Hydroxylase Inhibitors; Proline Dioxygenase Inhibitor; Proline Hydroxylase Inhibitor; Prolyl Hydroxylase Inhibitor; Prolyl-Hydroxylase Inhibitor

Networked: 412 relevant articles (34 outcomes, 70 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Prolyl-Hydroxylase Inhibitors: 412

Experts

1.	Nangaku, Masaomi: 29 articles (09/2022 - 12/2007)
2.	Akizawa, Tadao: 27 articles (09/2022 - 01/2017)
3.	Cobitz, Alexander R: 14 articles (01/2022 - 04/2016)
4.	Tanaka, Tetsuhiro: 12 articles (09/2022 - 01/2009)
5.	Eckardt, Kai-Uwe: 11 articles (09/2022 - 06/2003)
6.	Reusch, Michael: 11 articles (04/2022 - 01/2019)
7.	Neff, Thomas B: 9 articles (03/2021 - 10/2015)
8.	Cizman, Borut: 8 articles (01/2022 - 07/2018)
9.	Leong, Robert: 8 articles (01/2022 - 10/2015)
10.	Macdougall, Iain C: 8 articles (01/2022 - 01/2017)

Related Diseases

1.	Hypoxia (Hypoxemia) 05/01/2023 - "Hypoxia-inducible factor prolyl hydroxylase inhibitor was effective and safe for RTx patients regardless of prior ESA use." 01/01/2023 - "Hypoxia inducible factors-prolyl hydroxylase inhibitors (HIF-PHI) are oral agents with promising results. " 09/07/2023 - "In vivo studies were performed with mice exposed to 10% systemic hypoxia for 3 days or injected with 3,4-DHB (dihydroxybenzoate), a PHD (prolyl hydroxylase) inhibitor, 24 h prior analyses. " 01/01/2023 - "Recent clinical trials have shown the potential benefits of hypoxia-inducible factor prolyl hydroxylase inhibitors, especially as an oral agent in CKD patients. " 01/01/2022 - "Objective: This study aimed to explore the global research status, hot topics, and future prospects in the field of the hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) by bibliometric analysis. "
2.	Anemia 11/01/2018 - "Recent experimental and clinical studies show the promising efficacy of prolyl hydroxylase inhibitors in renal anemia through increasing EPO production by stabilizing HIF. " 01/29/2018 - "This article provides an overview of recent studies describing current standards of care for patients with anemia in CKD and associated clinical issues, and those supporting the clinical potential for targeting HIF stabilization with HIF prolyl-hydroxylase inhibitors (HIF-PHI) in these patients. " 01/01/2017 - "Results from clinical studies of a number of HIF prolyl hydroxylase inhibitors are increasingly available and provide support for the continued evaluation of the risk-benefit ratio of this novel therapeutic approach to the treatment of anemia in CKD." 01/01/2023 - "Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis." 01/01/2023 - "Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis."
3.	Chronic Renal Insufficiency 11/01/2022 - "Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors." 01/01/2020 - "Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease." 01/01/2020 - "Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?" 01/01/2023 - "Aim: We performed a systematic review and network meta-analysis evaluating the safety and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among dialysis chronic kidney disease patients. " 01/01/2023 - "A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease."
4.	Inflammation (Inflammations) 09/01/2017 - "Systemic administration of a HIF-prolyl hydroxylase inhibitor replicated the Phd2-deficient phenotype of delayed inflammation resolution. " 01/01/2023 - "Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs), as stabilizers of HIF, have recently been reported to have the ability to block inflammation. " 12/01/2020 - "Prolyl hydroxylase inhibitors (PHI) promote stabilization of hypoxia-inducible factor-1 alpha and affect signaling cascades of inflammation and cell death. " 06/01/2014 - "In contrast, pharmacologic or genetic activation of HIF via HIF prolyl-hydroxylase inhibition protected wild-type animals from ischemic kidney injury and inflammation; however, these same protective effects were not observed in HIF prolyl-hydroxylase inhibitor-treated animals lacking endothelial HIF-2. " 01/15/2019 - "In the current work using rodent models of inflammation, an orally available small molecule prolyl hydroxylase inhibitor desidustat was assessed as an effective treatment of anemia of inflammation. "
5.	Fibrosis (Cirrhosis) 07/01/1988 - "A prolyl hydroxylase inhibitor may be a candidate for use in treatment of hepatic fibrosis." 01/01/2021 - "now clearly show that activating the HIF signaling in the Gli1-lineage myofibroblasts restores erythropoietin production while not adversely affecting matrix production, mitigating the concerns of exacerbated fibrosis by HIF prolyl hydroxylase inhibitors." 01/01/2020 - "JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors." 11/01/2022 - "The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A." 11/28/2023 - "Hypoxia-inducible factor-prolyl hydroxylase inhibitor Roxadustat (FG-4592) reduces renal fibrosis in Dahl salt-sensitive rats."

Related Drugs and Biologics

1.	roxadustat
2.	Iron
3.	Hemoglobins (Hemoglobin)
4.	Erythropoietin
5.	GSK1278863
6.	Hematinics
7.	desidustat
8.	molidustat
9.	Hepcidins
10.	Transcription Factors (Transcription Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Transplantation
3.	Renal Dialysis (Hemodialysis)
4.	Renal Replacement Therapy (Therapies, Renal Replacement)
5.	Kidney Transplantation